Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 20 studies | 28% ± 10% | |
endothelial cell | 19 studies | 33% ± 16% | |
pericyte | 12 studies | 30% ± 8% | |
smooth muscle cell | 11 studies | 23% ± 8% | |
adipocyte | 10 studies | 44% ± 13% | |
oligodendrocyte precursor cell | 8 studies | 32% ± 15% | |
capillary endothelial cell | 8 studies | 30% ± 9% | |
myofibroblast cell | 7 studies | 28% ± 6% | |
connective tissue cell | 6 studies | 35% ± 12% | |
vein endothelial cell | 6 studies | 27% ± 10% | |
endothelial cell of lymphatic vessel | 4 studies | 25% ± 8% | |
GABAergic neuron | 4 studies | 22% ± 7% | |
endothelial cell of artery | 3 studies | 42% ± 17% | |
mesothelial cell | 3 studies | 18% ± 2% | |
type I pneumocyte | 3 studies | 23% ± 6% | |
endothelial cell of vascular tree | 3 studies | 19% ± 1% | |
glutamatergic neuron | 3 studies | 22% ± 4% | |
astrocyte | 3 studies | 33% ± 9% | |
interneuron | 3 studies | 32% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 11476.32 | 459 / 459 | 97% | 69.80 | 1088 / 1118 |
prostate | 99% | 6280.02 | 243 / 245 | 96% | 41.89 | 481 / 502 |
ovary | 100% | 10605.26 | 180 / 180 | 90% | 50.79 | 386 / 430 |
lung | 100% | 9186.27 | 577 / 578 | 87% | 42.37 | 1007 / 1155 |
intestine | 99% | 8763.92 | 958 / 966 | 74% | 21.31 | 392 / 527 |
uterus | 99% | 8793.85 | 168 / 170 | 68% | 45.08 | 310 / 459 |
kidney | 76% | 2611.66 | 68 / 89 | 87% | 44.84 | 787 / 901 |
bladder | 100% | 11622.52 | 21 / 21 | 64% | 20.77 | 321 / 504 |
esophagus | 72% | 4061.15 | 1043 / 1445 | 86% | 39.27 | 158 / 183 |
stomach | 72% | 3522.24 | 258 / 359 | 84% | 26.23 | 241 / 286 |
thymus | 91% | 2950.90 | 595 / 653 | 46% | 9.35 | 280 / 605 |
skin | 73% | 10713.26 | 1316 / 1809 | 49% | 24.18 | 232 / 472 |
adipose | 100% | 14473.84 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 11348.50 | 1333 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 63% | 1486.34 | 162 / 258 | 36% | 8.53 | 83 / 230 |
heart | 96% | 4529.88 | 823 / 861 | 0% | 0 | 0 / 0 |
pancreas | 6% | 153.85 | 21 / 328 | 87% | 33.30 | 155 / 178 |
spleen | 93% | 3309.35 | 224 / 241 | 0% | 0 | 0 / 0 |
brain | 12% | 245.97 | 321 / 2642 | 74% | 21.73 | 522 / 705 |
liver | 42% | 1052.73 | 95 / 226 | 27% | 6.11 | 109 / 406 |
tonsil | 0% | 0 | 0 / 0 | 64% | 20.91 | 29 / 45 |
muscle | 31% | 694.98 | 246 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 6.35 | 8 / 29 |
eye | 0% | 0 | 0 / 0 | 23% | 3.61 | 18 / 80 |
peripheral blood | 0% | 8.02 | 2 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051260 | Biological process | protein homooligomerization |
GO_0001525 | Biological process | angiogenesis |
GO_0098869 | Biological process | cellular oxidant detoxification |
GO_0042744 | Biological process | hydrogen peroxide catabolic process |
GO_0030198 | Biological process | extracellular matrix organization |
GO_0070207 | Biological process | protein homotrimerization |
GO_0007155 | Biological process | cell adhesion |
GO_0001654 | Biological process | eye development |
GO_0006955 | Biological process | immune response |
GO_0071711 | Biological process | basement membrane organization |
GO_0030199 | Biological process | collagen fibril organization |
GO_0006979 | Biological process | response to oxidative stress |
GO_0001960 | Biological process | negative regulation of cytokine-mediated signaling pathway |
GO_0070831 | Biological process | basement membrane assembly |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0031012 | Cellular component | extracellular matrix |
GO_0009986 | Cellular component | cell surface |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005604 | Cellular component | basement membrane |
GO_0004601 | Molecular function | peroxidase activity |
GO_0140825 | Molecular function | lactoperoxidase activity |
GO_0005201 | Molecular function | extracellular matrix structural constituent |
GO_0043237 | Molecular function | laminin-1 binding |
GO_0020037 | Molecular function | heme binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0016684 | Molecular function | oxidoreductase activity, acting on peroxide as acceptor |
GO_0005152 | Molecular function | interleukin-1 receptor antagonist activity |
Gene name | PXDN |
Protein name | PXDN protein Peroxidasin homolog (EC 1.11.2.-) (Melanoma-associated antigen MG50) (Peroxidasin 1) (hsPxd01) (Vascular peroxidase 1) (p53-responsive gene 2 protein) [Cleaved into: PXDN active fragment] Peroxidasin |
Synonyms | PXD01 VPO PRG2 VPO1 KIAA0230 MG50 |
Description | FUNCTION: Catalyzes the two-electron oxidation of bromide by hydrogen peroxide and generates hypobromite as a reactive intermediate which mediates the formation of sulfilimine cross-links between methionine and hydroxylysine residues within an uncross-linked collagen IV/COL4A1 NC1 hexamer . In turns, directly contributes to the collagen IV network-dependent fibronectin/FN and laminin assembly, which is required for full extracellular matrix (ECM)-mediated signaling . Thus, sulfilimine cross-links are essential for growth factor-induced cell proliferation and survival in endothelial cells, an event essential to basement membrane integrity . In addition, through the bromide oxidation, may promote tubulogenesis and induce angiogenesis through ERK1/2, Akt, and FAK pathways . Moreover brominates alpha2 collagen IV chain/COL4A2 at 'Tyr-1485' and leads to bromine enrichment of the basement membranes . In vitro, can also catalyze the two-electron oxidation of thiocyanate and iodide and these two substrates could effectively compete with bromide and thus inhibit the formation of sulfilimine bonds . Binds laminins . May play a role in the organization of eyeball structure and lens development during eye development (By similarity). . |
Accessions | ENST00000433670.5 H7C300 ENST00000453308.1 ENST00000425171.2 H7C3W2 ENST00000447941.5 ENST00000252804.9 [Q92626-1] H7C1W1 Q92626 C9J4I9 Q96GF5 |